DALLAS, TX / ACCESS Newswire / October 26, 2026 / Pepti LLC announced the launch of HelloPepti.com, a U.S. digital telehealth platform specializing in the coordination of physician-guided evaluations involving peptide-related medicine.

The platform began its initial rollout in September 2026. Its introduction marks the company's entry into the specialized telehealth technology sector.

Company Background

Pepti was founded in 2026 to develop digital infrastructure for a specialized segment of the U.S. telehealth industry.

The company's business model centers on technology and administrative coordination involving independent licensed healthcare professionals and pharmacy partners.

Pepti's focus on peptide-related telehealth distinguishes its business model from general-purpose digital healthcare platforms, without establishing comparative claims about treatment outcomes or clinical effectiveness.

Platform Development

HelloPepti.com serves as the company's primary digital platform. Its infrastructure incorporates online intake systems, medical evaluation workflows, patient account management and administrative coordination.

Independent healthcare professionals retain responsibility for clinical decisions, including whether any prescription is appropriate.

The company has also developed an online presence intended to provide information about its organization, operating model and approach to telehealth.

Regulatory Considerations

Pepti operates in an area of healthcare subject to federal and state requirements governing telemedicine, medical prescribing and pharmacy services.

The company does not independently practice medicine, issue prescriptions or dispense medications. Clinical and dispensing responsibilities remain with the applicable licensed professionals and pharmacies.

The company acknowledges that compounded medications are not FDA-approved and that treatment availability is subject to applicable legal and clinical requirements.

About Pepti

Pepti LLC is a U.S. healthcare technology company founded in 2026 and registered in Delaware. The company operates HelloPepti.com, a digital telehealth platform focused on technology and administrative support for physician-guided peptide treatment evaluations.

Company website: https://hellopepti.com

Media Contact
Pepti Media Relations
Pepti LLC
Email: hello@hellopepti.com
Phone: (469) 429-2851

SOURCE: Pepti LLC